NCT06635785招募中1 期
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- OncoC4, Inc.
- 入组人数
- 387
- 试验地点
- 35
- 主要终点
- Maximum tolerated dose (MTD)
研究概览
简要总结
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
详细描述
AI-081 is a bispecific antibody against PD-1 and VEGF. The study BiPAVE-001 is consisting of two integrated parts: Part A is the first-in-human dose escalation study to determine the recommended Phase 2 dose (RP2D) of AI-081 monotherapy, while Part B are dose optimization trials comparing the safety and clinical activities of AI-081 at RP2D and one dose level lower than RP2D (RP2D-1), either as monotherapy or in combination therapy with standard of care (SOC) in selected indications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is ≥ 18 years of age on the day of signing informed consent.
- •Male or female, female patient of childbearing potential must have negative pregnancy test.
- •Patient must have a performance status of ≤ 1 on the ECOG Performance Scale.
- •Patients must have a histological or cytological diagnosis of solid tumors and have metastatic disease or locally advanced disease.
- •Measurable disease as determined by RECIST 1.1
- •Patient must have adequate organ function as indicated by the following laboratory values
- •Patient has voluntarily agreed to participate by giving written informed consent.
- •Female patients enrolled in the study, if having childbearing potential (WOCBP) and sexually active, must agree to use adequate and effective birth control starting with the first dose of study drug through 90 days after the last dose of study therapy.
- •Male patients, if sexually active, must agree to use adequate and effective methods of contraception starting with the first dose of study drug through 90 days after the last dose of study therapy.
排除标准
- •Patients who have not recovered to NCI CTCAE grade ≤ 1 from an adverse event (AE) due to cancer therapeutics except the chemotherapy-associated peripheral neuropathy (motor or sensory) or alopecia. Patients with ongoing and adequately controlled endocrine immune-related AEs are considered stable and eligible for enrollment. The washout period for treatment regimen containing monoclonal antibodies is 28 days. Palliative radiotherapy for painful metastases or metastases in potentially sensitive locations (e.g., epidural space) ≥ 7 days prior to the first dose of study drug. Best supportive care, such as thyroxine, insulin, steroid replacement treatment, blood transfusion and therapy for non-cancer condition are allowed.
- •Patients who are currently enrolled in any other clinical trial testing an investigational agent or device, or with concurrent anticancer treatment (except palliative bone-directed radiotherapy), immune therapy, or cytokine therapy or anticipated to require another antineoplastic therapy during the study.
- •Patients who are on chronic systemic steroid therapy at doses higher than 10 mg/day prednisone or equivalent within 7 days before first treatment.
- •Patients who have brain metastases or leptomeningeal metastases.
- •Patient with a different cancer other than the one treated under this protocol, which requires systemic treatments within 24 months prior to C1D
- •Patient has history of grade ≥3 allergic or hypersensitivity to IV infusion medications, or severe allergic reactions to food, pollen, oral medications, or atopic dermatitis or asthmatic episodes that required hospitalization.
- •Within past 6 months with history of significant cardiovascular acute myocardial infarction, acute coronary syndrome, ischemic or hemorrhagic stroke, revascularization procedures, acute pulmonary embolism or any disorders resulted in LVEF < 40% at the time of screening or colitis, small bowel obstruction, hepatitis or pancreatitis adrenal insufficiency, or severe immunotherapy related AE (irAE≥ grade 3).
- •Patients who have acute infections which require systemic treatments within 14 days prior to C1D
- •Patients who, in the opinion of the treating Investigator, have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or make study participation not in the best interest of the patient, in the opinion of the treating Investigator. Investigators should discuss the case with the Sponsor and/or study leaders.
- •Patients with known psychiatric or substance abuse disorders may interfere with cooperation with the requirements of the trial.
- •Patients who are pregnant or breastfeeding or plan pregnancy or fathering the child during the study or within 6 months after the last dosing of study drug
- •Patients with tumor surrounds important blood vessels or has obvious necrosis, cavitation, or invades surrounding important organs and blood vessels or otherwise with high risk of fatal hemorrhage
- •Uncontrolled hypertension: systolic pressure ≥ 150 millimeters of mercury (mmHg) or diastolic pressure ≥ 90 mmHg on repeated measurements that cannot be managed by standard antihypertension medications ≤ 28 days before the first dose of study drug(s).
- •Medical history of cardiovascular diseases, gastrointestinal perforation or gastrointestinal fistula within 6 months prior to the first dose.
- •Patients with clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring frequent drainage.
- •With a history of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung diseases, etc.
研究组 & 干预措施
AI-081
Experimental
AI-081 will be given by IV infusion in designated dose, q3w.
干预措施: AI-081 (Drug)
结局指标
主要结局
Maximum tolerated dose (MTD)
时间窗: 21 Days
Maximal tolerable dose (MTD), the study drug, AI-081
Dose Limiting Toxicity (DLT)
时间窗: 21 Days
The number of subjects who have Dose limiting toxicity (DLT) as defined by protocol DLT criteria during the first cycle of study drug, AI-081, administration.
次要结局
- Cmax of AI-081(63 Days)
- The serum half-life of AI-081(63 Days)
研究者
研究点 (35)
Loading locations...
相似试验
已完成
1 期
Safety, PK and Efficacy of AI-061 in Advanced Solid TumorsNon Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaHigh Grade Serous Adenocarcinoma of OvaryFallopian Tube CancerEndometrial CancerGastroesophageal-junction CancerBile Duct CancerRenal Cell CarcinomaMelanomaPrimary Peritoneal CarcinomaBladder CancerColorectal CancerAnal CancerHepatocellular CarcinomaGastric CancerCervical CancerEsophageal CancerNCT05858736OncoC4, Inc.18
已完成
1 期
PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian ParticipantsHealthyTrigeminal NeuralgiaNCT02831517Biogen64
已完成
不适用
A study to detect the effect of radiofrequent ablation in combination with ipilimumab in patients with eye melanoma that spread out to the liver.uveal melanomaliver metastasesoog melanoomlever metastasenNL-OMON26122KI-AV44
已完成
1 期
Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis BChronic Hepatitis BNCT03109730Assembly Biosciences38
已完成
1 期
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)Purpura, Thrombocytopenic, IdiopathicNCT03275454Bioverativ, a Sanofi company12
相关资讯
FDA Grants Fast Track Designation to OncoC4's PD-1/VEGF Bispecific Cesalatamig for PD-(L)1-Refractory NSCLC- The FDA has granted Fast Track Designation to OncoC4's PD-1/VEGF bispecific antibody cesalatamig for NSCLC that progressed after PD-(L)1 immunotherapy and platinum-based chemotherapy.
- Cesalatamig, also known as AI-081, is being evaluated in global Phase 1/2 BiPAVE-001 trials in the United States and China across more than 50 clinical sites.
- OncoC4 says the designation reflects clinical safety and efficacy signals from the trials and supports rapid advancement to registrational Phase 3 development in PD-(L)1-refractory or resistant NSCLC.
- The antibody is engineered for high PD-1 affinity and more than 40-fold higher VEGF affinity than bevacizumab-based PD-(L)1/VEGF inhibitors, with Fc-silencing to spare PD-1 positive effector T cells.2 days agoOncoC4 Advances PD-1/VEGF Bispecific Antibody AI-081 to Phase 2 Trial Following Promising Early Efficacy Data- OncoC4 has dosed the first patient in the Phase 2 portion of the BIPAVE-001 trial evaluating AI-081, a potentially best-in-class PD-1/VEGF bispecific antibody for advanced solid tumors.
- The Phase 1 dose escalation demonstrated excellent safety, favorable pharmacokinetics, and objective anti-tumor response at the lowest tested dose of 1 mg/kg.
- AI-081 combines proprietary anti-PD1 and anti-VEGF antibodies in a head-and-tail bispecific configuration designed for enhanced dual-targeted immune responses.
- The Phase 2 trial will focus on dose optimization in non-small cell lung cancer, with 11 clinical sites actively enrolling patients across the United States.last year